Corazon Gold Corp.

• Corazon Gold schließt Privatplatzierung ab

  Corazon Gold Corp. meldete heute den Abschluss einer Privatplatzierung ohne Brokerbeteiligung, im Rahmen derer das Unternehmen insgesamt 1.316.000 Einheiten zum Preis von je 0,19$ veräußerte. Der Erlös daraus beläuft sich auf 250.040$. Jede Einheit besteht aus einer Stammaktie und einem halben Optionsschein, sodass insgesamt 658.000 Optionsscheine ausgegeben wurden.

  weiterlesen

  22.07.2015

  von Redaktion

• Corazon Gold and NanoSphere Announce Completion of $5.9 Million Financing and Merger

  Corazon Gold and NanoSphere Health Sciences are pleased to announce the closing of the Company’s private placement for gross proceeds of $5,905,685, and the completion of the Company’s acquisition of NanoSphere. Based upon the CSE’s conditional listing approval, the Company will make its final submission for CSE listing in short order, and concurrently with its listing on the CSE will change its [...]

  weiterlesen

  30.11.2017

  von GlobeNewswire
• Corazon Gold and NanoSphere Sign Binding Merger Agreement

  Corazon Gold is pleased to announce that it has completed its due diligence on NanoSphere Health Sciences LLC and has signed a binding Merger Agreement dated May 18th, 2017, to acquire 100% of the issued shares of NanoSphere through the merger of NanoSphere and a wholly-owned subsidiary of Corazon (see also Corazon’s press release dated January 5th 2017, available under the Company’s SEDAR profile at [...]

  weiterlesen

  05.06.2017

  von GlobeNewswire
• Corazon Gold Signs LOI to Acquire 100% of NanoSphere Health Sciences and Innovative Cannabinoid Delivery System

  Corazon Gold is pleased to announce that it has signed a Letter of Intent dated December 22, 2016, with NanoSphere Health Sciences LLC to acquire 100% of the issued and outstanding shares of NanoSphere. NanoSphere is a biotechnology company that has developed a multiple patent-pending, non-invasive delivery system for bioactive compounds such as cannabinoids, pharmaceuticals, over-the-counter drugs, nutraceuticals [...]

  weiterlesen

  05.01.2017

  von Marketwire
• Corazon Gold Corp. Announces Grant of Stock Options

  Corazon Gold is pleased to announce that that it has granted an aggregate of 2,390,017 stock options to certain directors, officers and consultants for the purchase of up to 2,390,017 common shares of the Company pursuant to its Stock Option Plan. Each option is exercisable for a period of 5 years at a price of $0.27 per common share. On behalf Corazon Gold Corp. Victor Goncalves, President and CEO Neither the TSX [...]

  weiterlesen

  21.09.2016

  von Marketwire
• Corazon Gold Corp. Announces Closing of Non-Brokered Private Placement

  Corazon Gold is pleased to announce that the company has completed a financing of $781,375 for a total of 3,906,875 units. On September 16, 2016, it completed a first tranche of the non-brokered private placement financing as further described in the news release of August 26, 2016. In connection with the closing of the First Tranche, the Company sold an aggregate of 3,081,875 units (each, a "Unit"), at a price of [...]

  weiterlesen

  20.09.2016

  von Marketwire

weitere engl. Meldungen